Replimune Group Target of Unusually Large Options Trading (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL) was the target of unusually large options trading activity on Tuesday. Investors purchased 11,386 call options on the company. This represents an increase of approximately 653% compared to the average daily volume of 1,513 call options.

Wall Street Analyst Weigh In

Several analysts have recently commented on REPL shares. Piper Sandler increased their target price on Replimune Group from $14.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, June 2nd. Cantor Fitzgerald assumed coverage on shares of Replimune Group in a research report on Friday, June 20th. They issued an “overweight” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Replimune Group in a research report on Thursday, July 3rd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $20.83.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 25,105 shares of the business’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $202,346.30. Following the transaction, the chief executive officer directly owned 343,576 shares in the company, valued at $2,769,222.56. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 7,952 shares of the firm’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the sale, the insider directly owned 146,933 shares of the company’s stock, valued at approximately $1,184,279.98. The trade was a 5.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,907 shares of company stock worth $603,655 over the last ninety days. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC boosted its holdings in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after buying an additional 1,655 shares during the last quarter. US Bancorp DE boosted its stake in Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after acquiring an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd increased its stake in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after purchasing an additional 8,183 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Replimune Group by 897.2% during the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company’s stock worth $902,000 after purchasing an additional 7,913 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Stock Up 9.9%

Shares of NASDAQ REPL opened at $12.40 on Wednesday. Replimune Group has a 1 year low of $6.44 and a 1 year high of $17.00. The firm’s 50-day moving average is $9.24 and its 200-day moving average is $10.48. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $955.92 million, a PE ratio of -4.04 and a beta of 0.61.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the company earned ($0.25) EPS. Equities analysts expect that Replimune Group will post -2.97 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.